Drug Master Files, manufacturer listings, and Electronic Common Technical Document (eCTD) submissions are foundational to regulatory compliance. Yet even experienced regulatory, quality, and operations...
The global Unique Device Identification (UDI) landscape is entering a critical enforcement phase — and 2026 will be a challenging year for medical device manufacturers operating in the European Union...
The FDA’s final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” establishes a uniform 12-digit format for FDA-assigned National Drug Codes (NDCs) ...
UDI product data is now due for specific scenarios (enforced as of December 8, 2022). Class I and Unclassified medical devices that are required to be labeled with a UDI code must submit product data...
LexisNexis Life Sciences Solutions and ONIX expand strategic alliance to guide pharma customers to market faster Professionals in the life sciences industry rely on unique regulatory affairs expertise...
As you work on implementing UDI, you may be wondering how to assign the Device Identifier (DI) portion of the UDI to your products and how to make sense of the different levels of DIs in a single GUDID record. These are questions we receive from industry members all the time.
After determining your issuing agency and obtaining a sufficient number of DIs, you will need to assign those DIs to the devices in your portfolio and report them as part of the DI record submission to the GUDID. Each DI record contains at least a Primary DI and possibly more:
For more detail on how to obtain, assign and manage DIs, download the LexisNexis Life Sciences eBook, UDI: A Guide to Device Identifiers. Inside is a useful diagram illustrating the different types of DIs, help on choosing an issuing agency and links to UDI resources.
Need help navigating regulatory complexity? Contact LexisNexis Life Sciences to learn how we can support your compliance and submission strategy.
Contact us